info_outline
The MCC - Avoca Quality Consortium Integration — Latest Developments with WCG AQC VP Michelle Webb and Senior Advisor Linda Sullivan
03/28/2022
The MCC - Avoca Quality Consortium Integration — Latest Developments with WCG AQC VP Michelle Webb and Senior Advisor Linda Sullivan
What’s the current status of the WCG Avoca Quality Consortium (AQC) — the exciting new collaboration between Metrics Champion Consortium (MCC) and Avoca Quality Consortium, whose mission is to elevate clinical trial quality, drive efficiency, and mitigate risk through industry collaboration by providing a more holistic approach to improving clinical trial operations. That’s the key topic explored during Senior Advisor Linda Sullivan’s interview with Michelle Webb, Vice President of WCG’s AQC. The consortium is a diverse, global organization of more than 180 members that includes pharmaceutical and biotech companies, sites, and clinical service providers, who come together to achieve alignment within the industry, according to Webb. The integration of MCC with the AQC has enabled members to access information in one resource and proves that “the whole is greater than the sum of its parts,” she adds. True integration, Webb explains, has begun as members are participating in both Communities of Practice, which was traditionally MCC-based, and in Leadership Advisory Boards, which were historically AQC-based. The main 2022 workstreams for the consortium, she notes, including innovation adoption, inspection readiness, provider qualification, risk-based quality management, site quality, safety and metrics development workgroups, all intertwine with the overall themes of expansion and inclusion. Webb and Sullivan also discuss the importance of brainstorming in consortium meetings representing a unique approach to engaging members. Finally, Webb points out how the consortium will be keeping members current on regulatory updates and new guidance documents.
/episode/index/show/clinicaltrialoptimization/id/22590191
